PSYENCE BIOMEDICAL Expands Advisory Board and Launches Phase IIb Trials Amid Stock Surge

Introduction

PSYENCE BIOMEDICAL LTD (NASDAQ: PBM) is a biotechnology company focused on the development and commercialization of natural psilocybin-derived therapies. Headquartered in the United States, the company operates at the intersection of medicine, commerce, and science, with R&D oversight by CEO Dr. Neil Maresky, MD. PSYENCE BIOMEDICAL LTD cultivates and manufactures its own active pharmaceutical ingredients in a federally licensed, ISO 22000-certified facility.

Corporate structure

PSYENCE BIOMEDICAL LTD maintains a workforce of approximately 11–50 employees. Leadership includes:

• Dr. Neil Maresky, MD (Chief Executive Officer and R&D lead), with prior experience at AstraZeneca and Bayer, responsible for psilocybin therapy advancements through clinical and regulatory pathways.
• Dr. Dan J. Stein (Scientific Advisory Board member), a specialist in psychopharmacology.
• Dr. Albert P. Garcia-Romeu (Chair of the Scientific Advisory Board), experienced in clinical trial design and psychedelic research.

The company’s capital-markets and business-development functions aim to leverage intellectual property and support sustainable growth.

Psilocybin therapy by Michał Parzuchowski

Recent developments and news

On July 23, 2025, PSYENCE BIOMEDICAL filed a Form S-8 registration to add 70,174 common shares under its 2023 Equity Incentive Plan, reflecting an effort to expand employee equity participation. Two days later, on July 25, 2025, the company submitted an amended annual report (Form 20-F/A) to the SEC, which updates disclosures for the fiscal year ending March 31, 2025.

In July 2025, the company announced the expansion of its Scientific Advisory Board with the addition of Dr. Dan J. Stein and collaboration with Dr. Albert P. Garcia-Romeu. PSYENCE confirmed a partnership with Empax Center to execute Phase IIb clinical trials targeting Adjustment Disorder in palliative care, with patient recruitment slated for Q3 2025 and topline data expected in the second half of 2025.

Financial and strategic aspects

As of July 31, 2025, PSYENCE BIOMEDICAL LTD’s stock closed at USD 7.24, reflecting a 34.07% increase on the day, with a trading volume of 3,761,105 shares on the NASDAQ. Detailed revenue and profitability metrics can be referenced in the June 25, 2025 20-F filing. Key strategic finance activities include:

• Employee retention via equity incentives (Form S-8, July 23, 2025).
• Ongoing R&D funding through partnerships and capital-markets access.
• Intellectual-property management focused on psilocybin formulation, production processes, and treatment protocols.

These initiatives support clinical development and capital structure optimization.

Market position and industry context

PSYENCE BIOMEDICAL LTD is identified as the first Nasdaq-listed psilocybin biopharmaceutical company. Its market focus includes palliative care indications such as anxiety, depression, and Adjustment Disorder among oncology patients. The company operates within an emerging psychedelic therapeutics sector, competing with both biotech firms and research institutions. Regulatory engagement is essential, given evolving FDA guidelines and international drug-approval frameworks. PSYENCE’s operations extend across multiple legal jurisdictions, supported by its cultivation and production capabilities.

tl;dr

As of July 31, 2025, PSYENCE BIOMEDICAL LTD (NASDAQ: PBM) shares increased 34.07% to USD 7.24 on a volume of 3.76 million. In July 2025, the company:

• Registered 70,174 additional shares for employee incentives (Form S-8, July 23).
• Filed an amended annual report (Form 20-F/A, July 25).
• Expanded its Scientific Advisory Board with Drs. Dan J. Stein and Albert P. Garcia-Romeu.
• Partnered with Empax Center to begin Phase IIb trials in Q3 2025, aiming for topline data in H2 2025.